The role of modern immunotherapy in metastatic urothelial cancer: mini review

The approval of immune checkpoint inhibitors (ICIs) has changed the treatment landscape in many aspects urothelial cancer (UC), both non-muscle-invasive bladder and muscle-invasive introduced concept long-term remission for some patients metastatic setting. Front-line chemotherapy remains superior at achieving initial control disease compared to front-line therapy. However, durable responses are limited by resistance. maintenance approach, sequencing with ICIs, could be considered a best worlds chemotherapy, which is maintained individuals avelumab. outcomes UC remain poor. There three steps improving these patients; first develop better drugs combinations therapies, second development novel biomarkers techniques select treatment, third area give most optimal